Moreover, this study did not show association between the sensitivity to the PARPi Olaparib and mutational signatures correlated to HR defects or BRCAness, as well as to specific CMS or mutations in KRAS and BRAF. RAD51-low score was found as an indicator of response (to PARP inhibitors and carboplatin) and patient outcome in two studies reported on ESMO Breast Cancer Virtual Congress 2021, and incorporation of RAD51 testing for clinical decision making in triple negative breast cancer was proposed [275,276]. This evidence concerns the gene RAD51 and triple-negative breast carcinoma.